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The new coronavirus pandemic brought the need for researchers to work tirelessly in the search for therapies or 
vaccines that would allow control of the spread of the virus around the world. Fortunately there are two RNA 
vaccines against COVID-19 that have finished clinical tests and are approved in some countries. They are the first 
third generation vaccines approved in history and in time record. But still have some concerns about safety of 
DNA/RNA vaccines. Here we bring a discussion about safety of DNA/RNA: can these vaccines be integrated to the 
genome? In fact, DNA vaccines have an infinite chance to integrate in the cell's genome, but this infinite chance is 
equal zero when used with RNA-based vaccines. The vaccines based on nucleic acid (DNA and RNA) have been 
corresponding in advantages, becoming promising alternatives to guarantee the immunization of the new coronavirus.  
Keywords: Vaccine; COVID-19; Coronavirus; RNA; DNA. 
 
Resumo 
A nova pandemia de coronavírus trouxe a necessidade de pesquisadores trabalharem incansavelmente na busca por 
terapias ou vacinas que permitissem controlar a disseminação do vírus pelo mundo. Felizmente, existem duas vacinas 
de RNA contra COVID-19 que concluíram os testes clínicos e foram aprovadas em alguns países. São as primeiras 
vacinas de terceira geração aprovadas na história e em registro de tempo. Mas, ainda temos algumas preocupações 
sobre a segurança das vacinas de DNA / RNA. Trazemos aqui uma discussão sobre a segurança do DNA / RNA: 
essas vacinas podem ser integradas ao genoma? Na verdade, as vacinas de DNA têm uma chance infinita de se 
integrar ao genoma da célula, mas essa chance infinita é igual a zero quando usadas com vacinas baseadas em RNA. 
As vacinas à base de ácido nucléico (DNA e RNA) têm se correspondido em vantagens, tornando-se alternativas 
promissoras para garantir a imunização do novo coronavírus. 
Palavras-chave: Vacina; COVID-19; Coronavírus; RNA; DNA. 
 
Resumen 
La nueva pandemia de coronavirus trajo la necesidad de que los investigadores trabajaran incansablemente en la 
búsqueda de terapias o vacunas que permitieran controlar la propagación del virus por todo el mundo. 
Afortunadamente, existen dos vacunas de ARN contra COVID-19 que han finalizado las pruebas clínicas y están 
aprobadas en algunos países. Son las primeras vacunas de tercera generación aprobadas en la historia y en el tiempo 
récord. Pero, todavía tenemos algunas preocupaciones sobre la seguridad de las vacunas de ADN / ARN. Aquí 
traemos una discusión sobre la seguridad del ADN / ARN: ¿se pueden integrar estas vacunas al genoma? De hecho, 
las vacunas de ADN tienen una posibilidad infinita de integrarse en el genoma de la célula, pero esta posibilidad 
infinita es igual a cero cuando se usa con vacunas basadas en ARN. Las vacunas basadas en ácido nucleico (ADN y 
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ARN) se han correspondido en ventajas, convirtiéndose en alternativas prometedoras para garantizar la inmunización 
del nuevo coronavirus. 
Palabras clave: Vacuna; COVID-19; Coronavirus; ARN. ADN. 
 
1. Introduction 
There were three recurrences of coronavirus (sarbecovirus) in the 21st century. The first was in 2002-2003 in China 
with Severe Acute Respiratory Syndrome Coronavírus 1 (SARS-CoV-1), the second was in Saudi Arabia in 2012-current with 
Middle East Coronavirus Respiratory Syndrome (MERS-CoV) and, more recently, in China, 2019-current, the new 
coronavirus called Severe Acute Respiratory Syndrome Coronavírus 2 (SARS-CoV-2) has emerged, the cause of the 
coronavirus disease 2019 (COVID-19) which has already claimed more than 1 million fatalities (Pacheco et al., 2020a). 
The new coronavirus probably came from bats and was first identified in Wuhan, China, in December 2019. SARS-
CoV-2 corresponds to a positive ribonucleic acid (RNA) virus, allowing the translation by host ribosomes after entering the 
cell. The surface structure of SARS-CoV-2 is composed of four main proteins: membrane proteins (M), protein that form the 
complete viral envelope (E), protein spike (S) that is used for fixation and entry into host cells through human angiotensin-
converting enzyme 2 (hACE2), and in the innermost layer is found the protein of the nucleocapsid (N) encasing viral genome 
(Koirala et al., 2020). Compared to SARS-COV-1 they have 79,6% of similarity, but the SARS-COV-2 spike protein receptor-
binding domain (RBD) interacts more efficiently with the hACE2, allowing for better adaptation to infection in humans 
(Pacheco et al., 2020a; Baric, 2020). 
Several attempts have been made to find treatment for COVID-19, yet almost all have failed or failed to achieve 
satisfactory results, placing even greater hope in possible new vaccines against COVID-19 (Pacheco et al., 2020a). Before the 
current pandemic, there was not even a standardization of treatments for coronavirus infections, now it is noticeable the need 
to increase the demand for production and dimensioning of therapies and vaccines, in order to guarantee the survival of the 
world population and future generations (Wu et al., 2020).  
Currently, there are 237 candidate vaccines being developed by laboratories around the world. In the clinical phase 
it corresponds to a total of 64, being 15 based on nucleic acid (RNA / DNA) platform, carrying a nucleotide sequence 
encoding the protein of interest (Who, 2020; Ye et al., 2020). Vaccines based on DNA / RNA platforms are also called third 
generation vaccines and, until now, there were no such vaccines approved for human use (Campos et al., 2020). 
The processing and manufacture of DNA and RNA-based vaccines offer advantages because they do not require 
cultures or fermentation processes, which are time-consuming and expensive, compared to other traditional vaccines that 
require these steps (Mufamadi, 2020). Some of the systems that are being further explored and used in the development of 
vaccines based on DNA / RNA are: liposomes, lipid nanoparticles (LNP), with electrophysiological methods, such as 
electroporation (Ye et al., 2020).  
Two RNA vaccines have already completed the final results and achieved more than 90% effectiveness. These 
vaccines are from Pfizer-BioNTech, first approved in the United Kingdom, and Moderna/NIH, first approved in the United 
States, both already being administered to the general population (Ledford, 2020; Pacheco et al., 2020b; Mahase, 2020a).  
Due to the new technology used, there is a certain insecurity in the general population if this type of vaccine that 
uses the genetic material, would be able to integrate into the human genome and cause changes such as, for example, silencing 
tumor suppressor genes or activating oncogenes. 
Here we bring a brief explanation to elucidate this theme that has been questioned a lot by many people of the non-







The textual production of this study was developed based on the scientific literature in PubMed, Scielo, and Google 
Scholar databases. According to the indexes of the various databases, search terms were used: “vaccines for COVID-19”, 
“COVID-19”, “DNA vaccines”, “RNA vaccines”, without any language restrictions. 
 
3. Do DNA Vaccines Integrate Into the Genome? 
There are currently eight DNA-based candidates vaccines in the clinical phase against COVID-19 (Who, 2020) 
(Table 1). Some studies have analyzed the possibility of integrating DNA from vaccines into the human genome, a factor that 
could cause the silencing of tumor suppressor genes or the activation of oncogenes (Wang et al., 2004). However, experiments 
have already proven that this occurrence in mice is about 1000 copies/μg DNA, an integration frequency below the 
spontaneous rate of gene-inactivating mutations (Wang et al., 2004). 
However, vectors modified in order to increase immunogenicity may increase the chances of integration into the 
human genome, but there is no report to date on this either in preclinical or clinical tests (Fig. 1). Therefore, the evidence only 
reinforces the lack of proof that COVID-19 DNA vaccines could be integrated into the human genome, causing changes in 
oncogenes or tumor suppressor genes (Kutzler; Weiner, 2008; Naik; Peden, 2020).  
 
Table 1. Landscape of candidate vaccines in clinical phase based on DNA. (on January 2021). 
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Figure 1. DNA vaccines can integrate into the genome at a lower rate than spontaneous mutations. RNA vaccines are not able 
to integrate into the genome. 
 
Source: Authors (2020). 
 
4. Do RNA Vaccines Integrate into the Genome?  
With the advent of advantageous DNA and RNA vaccines, vaccine production time has been reduced dramatically. 
All it takes is just the antigen gene to make the vaccine (13). There are currently seven RNA-based candidates vaccines in the 
clinical phase (Who, 2020) (Table 2). Although it still does not have approved DNA vaccines, there are two RNA vaccines 
approved against COVID-19. Pfizer-BioNTech and Moderna-NIH vaccines work in a similar way (Pacheco et al., 2020b, 
Mahase, 2020b). But both consist of lipid nanoparticles that encase RNA and encode modified form of the SARS-CoV-2 spike 
protein to trigger immune response when translated into ribosomes.  
The two vaccines differ in the lipid nanoparticles that encapsulate RNA (Ledford, 2020). Whilst there is an infinite 
concern that DNA vaccines will integrate into the genome, using an RNA vaccine this problem is solved, since RNA does not 
enter the nucleus where the cell’s human genome resides (Figure 1) (Ledford, 2020, Naik; Peden, 2020; Mahase, 2020b; Liu, 
2019; Ulmer et al., 2012; Fuller; Berglund, 2020). In addition, there is a great possibility for other products using RNA 





Table 2. Landscape of candidate vaccines in clinical phase based on RNA. (On January 2021). 
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Fonte: Who (2020). 
 
5. Final Considerations 
There are no reports of DNA vaccines that have integrated into the host cell genome by silencing tumor suppressor 
genes or activating oncogenes, there is an infinite possibility that this will occur and it is less than spontaneous mutation. 
Using RNA in vaccines, the possibility of integrating genetic material into the genome is excluded, further strengthening the 
safety of these products. There are two RNA vaccines approved against COVID-19 and there is no possibility to integrate into 
the human genome.  
It’s evident that knowledge and understanding about the disease and the causative virus, COVID-19 and SARS-
CoV-2 respectively, are increasingly being consolidated among researchers, government officials and society. However, 
confusion and the spread of false information represent a danger to all of us. Therefore, studies developed, such as presented 
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here, are pertinent to clarify for society, including for the enrichment of the scientific community's knowledge about vaccines 
based on nucleic acid and the peculiarities involved, as well as the update on those that are already being distributed globally. 
We know it’s still too early to assess whether the vaccines being made available will be able to minimize or 
eradicate the current pandemic. So, probably, our next studies may be related to this approach. 
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